Left atrial appendage closure—promise meets proof, and proof meets pause.

Left atrial appendage closure—promise meets proof, and proof meets pause.   In The New England Journal of Medicine, two pivotal trials draw a nuanced arc: CHAMPION-AF shows noninferior stroke prevention with less bleeding vs direct oral anticoagulants, while CLOSURE-AF tempers enthusiasm—failing noninferiority in older, high-risk patients with meaningful procedural risk.   The message is elegant and sobering: innovation must bow to evidence, and patient selection remains paramount.   In atrial fibrillation, the art lies not in closing the appendage—but in opening judgment.